Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Podobne zapisy

• Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
  od: van der Heijde, Désirée, i wsp.
  Wydane: (2015)
• Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
  od: Sieper, Joachim, i wsp.
  Wydane: (2011)
• Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
  od: van der Heijde, Désirée, i wsp.
  Wydane: (2009)
• Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
  od: Rudwaleit, Martin, i wsp.
  Wydane: (2010)
• Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
  od: van der Heijde, D, i wsp.
  Wydane: (2008)